07:00 , Apr 24, 2014 |  BC Innovations  |  Targets & Mechanisms

Reversing (heart) failure in Friedreich's ataxia

Heart failure accounts for over half the deaths in patients with Friedreich's ataxia, but no therapies exist to treat this neurodegenerative disease or its associated cardiomyopathy. Now, a team of French researchers has shown that...
07:00 , Oct 8, 2012 |  BioCentury  |  Product Development

Boosting mitochondria

Edison Pharmaceuticals Inc. plans to bring EPI-743 into Phase IIb testing this quarter after leveraging insights gained from an expanded access protocol to score a positive Phase IIa result in Leigh disease. The company is...
07:00 , Jun 20, 2011 |  BC Week In Review  |  Clinical News

Alpha-tocopherol quinone: Preliminary Phase IIa data

Preliminary data from a double-blind, U.S. Phase IIa trial in 31 patients showed that once-daily 1 and 1.5 mg oral EPI-A0001 each missed the primary endpoint of significantly improving glucose disposition index as measured by...
23:56 , Jun 13, 2011 |  BC Extra  |  Clinical News

Edison reports Phase II data in Friedreich's ataxia

Edison Pharmaceuticals Inc. (San Jose, Calif.) said EPI-A0001 missed the primary endpoint in a Phase IIa trial to treat Friedreich's ataxia. The product did not significantly improve glucose disposition index as measured by an IV...
07:00 , Jun 28, 2010 |  BioCentury  |  Finance

Activists take Penwest

Activists take Penwest Activist shareholders now hold five of the eight board seats at Penwest Pharmaceuticals Co. (NASDAQ:PPCO), and will likely use their majority to monetize the drug delivery company's assets and return more cash...
07:00 , Jun 28, 2010 |  BC Week In Review  |  Company News

Penwest drug delivery news

In a letter to shareholders earlier this month, Tang and Perceptive said Penwest management has not acted on a proposal to immediately wind down the company's operations despite the proposal's approval at last year's annual...
08:00 , Feb 15, 2010 |  BC Week In Review  |  Clinical News

Alpha-tocopherol quinone: Phase IIa started

Penwest began a double-blind, placebo-controlled, U.K. Phase IIa trial in 30 patients to evaluate A0001 for 28 days. Penwest has exclusive, worldwide rights to develop and commercialize A0001 from Edison (see BioCentury, July 23, 2007)....
08:00 , Jan 21, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Metabolic disease Mitochondrial disease Creatine (Cr) Studies in cell culture and in human plasma suggest that creatine could help diagnose inherited mitochondrial respiratory-chain diseases. In cultures...
08:00 , Jan 18, 2010 |  BC Week In Review  |  Clinical News

Alpha-tocopherol quinone: Phase IIa started

Last month, Penwest began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 1.0 and 1.5 mg/day oral A0001 given for 28 days in 42 patients. Penwest has exclusive, worldwide rights to develop and commercialize...
07:00 , Aug 3, 2009 |  BC Week In Review  |  Clinical News

Alpha-tocopherol quinone: Phase Ib data

Data from a single-blind, placebo-controlled, multiple ascending-dose Phase Ib trial in 40 healthy volunteers showed that A0001 was well tolerated with no serious adverse events. The maximum tolerated dose (MTD) was established, but the company...